Salivary PSA levels correlate with serum PSA levels in patients with prostate adenocarcinoma. miR-21 and miR-141 are two tumour biomarkers whose levels are significantly elevated in patients with early-stage and advanced-stage prostate cancer, respectively. This evidence concerns the gene PROS1 and prostate carcinoma.